Natriuretic peptides: diagnostic and prognostic significance in chronic kidney disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Проанализированы данные о диагностическом и прогностическом значении натрийуретических пептидов как маркеров сердечно-сосудистого риска при хронической болезни почек.

Full Text

Restricted Access

References

  1. Fassett R., Venuthurupalli S.K., Gobe G.C. Biomarkers in chronic kidney disease. Kidney Int. 2011; 80: 806—821.
  2. Комитет экспертов ОССН. Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности. Сердечная недостаточность. 2010. Т. 11. №1 (57): 3—62.
  3. Vassale C., Andreassi M.G. Genetic polymorphism of the natriuretic peptide system in pathogenesis of cardiovascular disease: what lies on the horizon? Clin Chem. 2009; 55:5: 878-887.
  4. Елисеев О.М. Натрийуретические пептиды. Эволюция знаний. Тер. архив. 2003; 9: 40-45.
  5. Hajjar V., Schreiber M.J. Does measuring natriuretic peptides have a role in patints with chronic kidney disease? Cleveland clinic journal of medicine. 2009:76; 476-478.
  6. Melanson S.E.F., Lewandrowski E.L. Laboratory testing for B-type natriuretic peptides (BNP and NT-proBNP). Am J Clin Pathol. 2005;124 (Suppl. 1): S122-S128.
  7. Niizuma S., Iwanaga Y., Yahata T. et al. Plasma B-type natriuretic peptide levels reflect the presence and severity of stabile coronary artery disease in chronic haemodialysispatients. Nephrol Dial Transplant. 2009; 24: 597-603.
  8. Николаев А.Ю., Милованов Ю.С. Лечение почечной недостаточности. Руководство для врачей. М., 2011. 592 с.
  9. Wang Y.-M.A., Lai K.-N. Use of cardiac biomarkers in end-stage renal disease. J. Am. Soc. Nephrol. 2008; 19: 1643-1652.
  10. Zoccali C., Mallamaci F., Benedetto F. et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J. Am. Soc. Nephrol. 2001; 12:1508-1515.
  11. Foley R.N., Curtis B.M., Randell E.W. et al. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin. J Am. Soc. Nephrol. 2010; 5: 805-813.
  12. Sanjuan R., Oliva S.M., Blasco M.L. et al. Plasma brain natriuretic peptide levels in cardiac function assessment in chronic dialysis patients. Cardiorenal Med. 2011;1:147-155.
  13. Ильичева О.Е., Харламова У.В., Нездоймина Н.Н. Мозговой натрийуретический пептид и риск сердечно-сосудистых событий у пациентов на гемодиализе. Нефрология и диализ. 2010. Т. 12. № 4. С. 263-265.
  14. Takase H., Dohi Y., Toriyama T. et al. B-type natriuretic peptide levels and cardiovascular risk in patients with diastolic dysfunction on chronic haemodialysis: cross-sectional and observation studies. Nephrol. Dial. Transplant. 2011;26: 683-690.
  15. Mark P.B., Stewart G.A., Gansevoort R.T. et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant. 2006; 21:402-410.
  16. Mallamaci F., Zoccali C., Tripepi G. et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001; 59:1559-1566.
  17. Wang Y.-M.A., Lam C.W.-K., Wang M. et al. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant. 2009;24:1962-1969.
  18. Tagore R., Ling L.H., Yang H. et al. Natriuretic peptides in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2008; 3:1644-1651.
  19. Davis S., Kümpers P., Seidler V. et al. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol. Dial. Transplant. 2008;23:1370-1377.
  20. Weber M., Arnold R. et al. N-terminal pro-B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stabile angina pectoris. Am. Heart J. 2004;148:612-620.
  21. DeFilippi C.R., Fink J.C., Nass C.M. et al. N-terminal pro-B-type natriuretic peptide for predicting coronary artery disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am. J. Kidney Dis. 2005;46:35-44.
  22. Booth J., Pinney J., Davenport. N-terminal pro-BNP - marker of cardiac dysfunction, fluid overload or malnutrition in hemodialysis patients? Clin. J. Am. Soc. Nephrol. 2010; 5:1036-1040.
  23. Chazot C., Vo-Van C., Zaoui E. et al. Fluid overload correction and cardiac history influence brain natriuretic peptide evolution in incident haemodialysis patients. Nephrol. Dial. Transplant. 2011; 26: 2630-2634.
  24. Jacobs L.H., van de Kerkhol J.J., Mingls A.M. et al. Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. Nephrol. Dial. Transplant. 2010; 25: 243-248.
  25. Sheen V., Bhalla V., Tulua-Tata A. et al. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am. Heart. J. 2007;153:244.e1-e5.
  26. Odar-Cederlöf I., Bjellerup P., Williams A. et al. Daily dialysis decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunction. Hemodial Int. 2006;10:394-398.
  27. Wahl H.G., Graf S., Renz H., Fassbinder W. Elimination of cardiac natriuretic peptides B-type (BNP) and N-terminal proBNP by hemodialysis. Clin Chem. 2004;50: 1071-1074.
  28. Racek J., Kralova H., Trefil L. et al. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron. Clin. Pract. 2006;103: 162-172.
  29. Iwashima Y., Horio T., Takami Y. et al. Effects of creation of the arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRS. Am. J. Kidney Dis. 2002;40:974-982.
  30. Yang J.W., Kim M.S., Kim J.S. et al. Relationship between brain natriuretic peptide and heart function in patients with chronic kidney disease. Korean J. Int. Med. 2008;23:191-200.
  31. Park S., Cho G.-Y., Kim S.G. et al. Brain natriuretic peptide levels have diagnostic and prognostic capability for cardio-renal syndrome type 4 in intensive care unit patients. Critical Care. 2009; 13 (3): R70 (doi 10.1186/ cc7878)
  32. Mallamaci F., Tripepi G., Currupi S. et al. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction and myocardiopathy in patients with ESRD. Kidney Int. 2005;67:2330-2337.
  33. Satyan S., Light R.P., Agarwal R. Relationship of N-terminal pro-B-type natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am. J. Kidney Dis. 2007; 50 (6): 1009-1019.
  34. Paniagua R., Ventura M.-de-J., Avila-Diaz M. et al. NT-proBNP, fluid overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol. Dial. Transplant. 2010; 25: 551-557.
  35. Wang Y.-M.A., Lam C.W.-K., Yu C.-M. et al. N-terminal pro-Brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J. Am. Soc. Nephrol. 2007; 18: 321-330.
  36. Austin W.J., Bhalla V., Hernandez-Arse I. et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am. J. Clin. Pathol. 2006; 126: 506-515.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies